- Home
- JFR vs ATRC Comparison
JFR vs ATRC Comparison
Compare JFR & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- ATRC
- Stock Information
- Founded
- JFR 2004
- ATRC 2000
- Country
- JFR United States
- ATRC United States
- Employees
- JFR N/A
- ATRC N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- ATRC Medical/Dental Instruments
- Sector
- JFR Finance
- ATRC Health Care
- Exchange
- JFR Nasdaq
- ATRC Nasdaq
- Market Cap
- JFR 1.2B
- ATRC 1.1B
- IPO Year
- JFR N/A
- ATRC 2005
- Fundamental
- Price
- JFR $8.66
- ATRC $38.47
- Analyst Decision
- JFR
- ATRC Strong Buy
- Analyst Count
- JFR 0
- ATRC 9
- Target Price
- JFR N/A
- ATRC $41.78
- AVG Volume (30 Days)
- JFR 621.7K
- ATRC 535.9K
- Earning Date
- JFR 01-01-0001
- ATRC 02-13-2025
- Dividend Yield
- JFR 11.31%
- ATRC N/A
- EPS Growth
- JFR N/A
- ATRC N/A
- EPS
- JFR N/A
- ATRC N/A
- Revenue
- JFR N/A
- ATRC $447,573,000.00
- Revenue This Year
- JFR N/A
- ATRC $17.75
- Revenue Next Year
- JFR N/A
- ATRC $13.44
- P/E Ratio
- JFR N/A
- ATRC N/A
- Revenue Growth
- JFR N/A
- ATRC 17.56
- 52 Week Low
- JFR $7.61
- ATRC $18.94
- 52 Week High
- JFR $8.82
- ATRC $39.12
- Technical
- Relative Strength Index (RSI)
- JFR 33.65
- ATRC 70.10
- Support Level
- JFR $8.89
- ATRC $31.00
- Resistance Level
- JFR $9.08
- ATRC $34.11
- Average True Range (ATR)
- JFR 0.10
- ATRC 1.76
- MACD
- JFR -0.04
- ATRC 0.86
- Stochastic Oscillator
- JFR 12.50
- ATRC 93.03
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.